ClinicalTrials.gg
CompletedNCT01969695Updated Dec 19, 2019

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

A Phase 1 interventional study of ABT-199 in Non-Hodgkin's Lymphoma, sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-12-19.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, 1 of them phase 3. venetoclax · Lymphoma, Non-Hodgkin.

Enrollment
19th of 23
11 · median 25
Started
2013
with 2 others
Phase 1
15 of 23
2 open now
Registered
3rd of 23
by date
Lead sponsor
10 of 23
AbbVie

Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, this one is the 19th largest by enrollment, is one of 3 that started in 2013, is one of 15 in phase 1, and was the 3rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma [CLL], small lymphocytic lymphoma [SLL], and mantle cell lymphoma [MCL]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.

03

Conditions studied

  • Non-Hodgkin's Lymphoma

Keywords

  • ABT-199
  • Cancer
  • GDC-0199
  • non-Hodgkin's lymphoma
  • Relapsed
  • Refractory
  • Safety
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has completed a prior ABT-199 study (and had met the criteria for a diagnosis of NHL and all other eligibility criteria for the previous study) and the investigator believes that treatment with ABT-199 is in the best interest of the subject.

Exclusion criteria

Exclusion Criteria:

  • Subject discontinued ABT-199 administration before completing the prior study (due to disease progression, toxicity, withdrawn consent, other).
  • Subject has any medical condition that in the opinion of the investigator places the subject at an unacceptably high risk for toxicities.
  • Subject has not recovered to ≤ Grade 2 adverse effect(s)/toxicity(ies) of previous therapy.
  • Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD), Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    ABT-199

    ABT-199 monotherapy

    Drug: ABT-199

Interventions

  • ABT-199 continuous once daily dosing

    Also known as: GDC-0199

06

What researchers measure

Primary outcomes

  1. Change in cardiac assessment findings

    Electrocardiogram and Multi Gated Acquisition Scan and/or Echocardiogram

    Time frame: Measured from Day 1 up to 6 years after the last subject has enrolled in the study

  2. Percentage of subjects with adverse events

    Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study

    Time frame: Measured up to 6 years after the last subject has enrolled in the study

  3. Change in clinical laboratory test results

    Chemistry, coagulation, hematology, lymphocyte enumeration, paraproteins, urinalysis, and, if appropriate, viral polymerase chain reaction and viral serologies

    Time frame: Measured from Day 1 up to 6 years after the last subject has enrolled in the study

  4. Number of subjects with adverse events

    Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study

    Time frame: Measured up to 6 years after the last subject has enrolled in the study

  5. Change in physical exam finding, including vital signs

    Body temperature, weight, blood pressure, heart rate

    Time frame: Measured from Day 1 up to 6 years after the last subject has enrolled in the study

07

Study locations

3 sites
  • University of Arizona Arthritis Center /ID# 101359
    Tucson, Arizona 85719-1478, United States
  • Dartmouth-Hitchcock Med Ctr /ID# 92596
    Lebanon, New Hampshire 03756, United States
  • Hackensack Univ Med Ctr /ID# 101417
    Hackensack, New Jersey 07601, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Dec 2019, 71 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 71 months is above that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Oct 25, 2013
StartActual
Dec 20, 2013
Primary completionActual
Dec 16, 2019
CompletionActual
Dec 16, 2019
Last update
Dec 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01969695
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 25, 2013
Start date
Dec 20, 2013
Primary completion
Dec 16, 2019
Completion
Dec 16, 2019
Last update
Dec 19, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion